Details for Patent: 8,962,028

✉ Email this page to a colleague

Which drugs does patent 8,962,028 protect, and when does it expire?

Patent 8,962,028 protects ULTRAVATE and is included in one NDA.

This patent has twenty-two patent family members in eighteen countries.

Summary for Patent: 8,962,028

Title:	Topical steroid composition and method
Abstract:	Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include a halobetasol material comprising halobetasol or its pharmaceutically acceptable salts, esters, and solvates; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include 0.05% halobetasol propionate; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate.
Inventor(s):	Johnson; Keith A. (Durham, NC), Popp; Karl F. (Schodack Landing, NY)
Assignee:	MiCal Pharmaceuticals LLC--H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company (San Diego, CA)
Application Number:	13/921,833
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,962,028
Patent Claim Types: see list of patent claims	Use; Composition; Delivery; Formulation; Device;

Drugs Protected by US Patent 8,962,028

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mical Pharms	ULTRAVATE	halobetasol propionate	LOTION;TOPICAL	208183-001	Nov 6, 2015		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,962,028

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013331271	⤷ Sign Up
Brazil	112015008951	⤷ Sign Up
Canada	2888853	⤷ Sign Up
China	104884043	⤷ Sign Up
Eurasian Patent Organization	029494	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.